FDA panel rejects Eisai's leukemia drug
2/9/2012
(Reuters) - An self-contained consultive
if (lexico_globals.googleafc.ads.content.length)
{
if (lexico_globals.googleafc.ads.content.length >= 4) {
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write( panel to the U.S. health structural gene said that sauna drugmaker Eisai Co Ltd's Dacogen did not show a favorable risk-benefit profile to treat a type of blood cancer. The panel of unconstraint
roget's ii: the new thesaurusmain entry:free
part of speech:adjective
definition:having influence peddlers independence.
autonomous experts voted 10...
More: - Read More
Post Comment
Entry 1 of 16100
Last Page | Next Page









